Local expression of myocardial galectin-3 does not correlate with its serum levels in patients undergoing heart transplantation

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 643-650

  Beiras Fernandez, Andres ^a   Weis, Florian ^b   Rothkopf, Julia ^b   Kaczmarek, Ingo ^b   Ledderose, Carola ^b   Dick, Andrea ^b   Keller, Till ^a   Beiras, Andres ^c   Kreth, Simone ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Fibrosis; Galectin 3; Heart transplantation

Indexed keywords

GALECTIN 3;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSING ALVEOLITIS; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE INJURY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY;

ADULT; BIOLOGICAL MARKERS; FEMALE; GALECTIN 3; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; STROKE VOLUME;

EID: 84890868437     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.889396     Document Type: Article

References (24)

1. de Boer RA, van Veldhuisen DJ, Gansevoort RT et al: The fibrosis marker galectin-3 and outcome in the general population. J Intern Med, 2012; 272(1): 55-64.
2. Dumic J, Dabelic S, Flögel M: Galectin-3: an open-ended story. Biochim Biophys Acta, 2006; 1760(4): 616-35.
3. YANG RY, Hill PN, Hsu DK, Liu FT: Role of the carboxyl-terminal lectin domain in self-association of galectin-3. Biochemistry, 1998; 37(12): 4086-92.
4. de Boer RA, Lok DJ, Jaarsma T et al: Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med, 2011; 43(1): 60-68.
5. Sharma UC, Pokharel S, van Brakel TJ et al: Galectin- 3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction. Circulation, 2004; 110(19): 3121-28.
6. Henderson NC, Mackinnon AC, Farnworth SL et al: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol, 2008; 172(2): 288-98.
7. Gullestad L, Ueland T, Kjekshus J et al., CORONA Study Group: Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J, 2012; 33(18): 2290-96.
8. Milting H, Ellinghaus P, Seewald M et al: Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant, 2008; 27(6): 589-96.
9. van Kimmenade RR, Januzzi JL Jr, Ellinor PT et al: Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol, 2006; 48(6): 1217-24.
10. Lopez-Andres N, Rossignol P, Iraqi W et al: Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail, 2012; 14(1): 74-81.
11. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 2001; 29(9): e45.
12. Vandesompele J, De Preter K, Pattyn F et al: Genome Biol. Accurate normalization of realtime quantitative RT-PCR data by geometric averaging of multiple internal control genes. 2002; 3(7): RESEARCH0034.
13. Pérez S, Royo LJ, Astudillo A, Escudero D et al: Identifying the most suitable endogenous control for determining gene expression in hearts from organ donors. BMC Mol Biol, 2007; 8: 114.
14. Liu YH, D'Ambrosio M, Liao TD et al: N-acetylseryl- aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol, 2009; 296: H404-12.
15. Erkilet G, Özpeker C, Böthig D et al: The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. J Heart Lung Transplant, 2013; 32(2): 221-30.
16. Yu L, Ruifrok WP, Meissner M et al: Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail, 2013; 6(1): 107-17.
17. Lok DJ, Van Der Meer P, de la Porte PW et al: Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol, 2010; 99(5): 323-28.
18. Felker GM, Fiuzat M, Shaw LK et al: Galectin- 3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail, 2012; 5(1): 72-78.
19. McCullough PA, Olobatoke A, Vanhecke TE: Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med, 2011; 12(4): 200-10. Erratum in: Rev Cardiovasc Med, 2012; 13(1): e52.
20. Newlaczyl AU, Yu LG: Galectin-3 - a jack-ofall- trades in cancer. Cancer Lett, 2011; 313(2): 123-28.
21. Rodrigues HG, de Pontes AA, Adan LF: Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr J, 2012; 59(5): 417-24.
22. Nozyński J, Zakliczyński M, Konecka-Mrowka D et al: Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. Ann Transplant, 2012; 17(2): 53-61.
23. Righi A, Jin L, Zhang S et al: Identification and consequences of galectin-3 expression in pituitary tumors. Mol Cell Endocrinol, 2010; 326(1-2): 8-14.
24. Tetaz R, Trocmé C, Roustit M et al: Predictive diagnostic of chronic allograft dysfunction using urinary proteomics analysis. Ann Transplant, 2012; 17(3): 52-60